The Biocidal Products Regulation – or, more precisely, the Regulation (EU) 528/2012 concerning the making available on the market and use of biocidal products – is intended to improve the functioning of the biocidal market and to protect humans, animals, and the environment. The Biocidal Products Regulation (BPR) applies from 1 September 2013 and requires your action when you market biocidal products.
The Biocidal Products Regulation stipulates that for all biocidal products an authorisation is required by the applicable deadline. Only then can you continue to market your products. The deadline is based on the biocidal active substances used. These must be approved for the relevant product type. After approval of the active substances, an authorisation dossier for the biocidal product must be compiled.
Because the definition of a biocidal product has changed, in situ systems are now also subject to the Biocidal Products Regulation. Both agents that are generated in situ with the appropriate equipment as well as the precursors themselves, which generate active ingredients in situ, must be authorised. Although previously not affected, marketers of these in situ systems are now subject to the regulation.
The BPR also now covers articles that have been treated with biocidal products. Such treated articles must contain only active substances that have been approved or are pending approval. In addition, there are certain requirements for labelling and information.
If a treated article has a primary biocidal function (i.e. it should not only protect itself), it is considered a biocidal product and must be authorised accordingly. The distinction between treated articles and biocidal products is not always clear and may depend on individual decisions. The Biocidal Products Regulation can represent challenges for your company. Not only in terms of defining your obligations but also in their implementation and the obtaining of an official authorisation aimed at safeguarding the future of your product. ⇒ Contact